Literature DB >> 26898097

[Therapeutic Angiogenesis Using Growth Factors: Current State and Prospects for Development].

P I Makarevich, K A Rubina, D T Diykanov, V A Tkachuk, Ye V Parfyonova.   

Abstract

Therapeutic angiogenesis has been in use for treatment of ischemic diseases for about 15 years. During this period of successes and failures this field has accumulated a significant amount of published and ongoing surveys giving insights and raising new questions and problems. One of the most utilized methods for therapeutic angiogenesis suggests introduction of angiogenic growth factors (VEGF, bFGF, angiopoietin-1 etc.) into ischemic tissues. Still, there is a whole range of problems regarding the efficacy of therapeutic angiogenesis. These can be potentially circumvented by use of new delivery methods, development of combined approaches and use of more relevant pre-clinical animal models. Present review gives a brief analysis of crucial achievements and issues that has been recently raised in experimental and clinical studies focusing on therapeutic angiogenesis. Final part brings some possible directions for development that can give an opportunity to circumvent current obstacles and provide further development.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26898097     DOI: 10.18565/cardio.2015.9.59-71

Source DB:  PubMed          Journal:  Kardiologiia        ISSN: 0022-9040            Impact factor:   0.395


  2 in total

1.  Implantable porous gelatin microspheres sustained release of bFGF and improved its neuroprotective effect on rats after spinal cord injury.

Authors:  Li Lan; Fu-Rong Tian; De-Li ZhuGe; Qi-Chuan ZhuGe; Bi-Xin Shen; Bing-Hui Jin; Jian-Ping Huang; Ming-Ze Wu; Lu-Xin Fan; Ying-Zheng Zhao; He-Lin Xu
Journal:  PLoS One       Date:  2017-03-14       Impact factor: 3.240

2.  A Fibroblast Growth Factor Antagonist Peptide Inhibits Breast Cancer in BALB/c Mice.

Authors:  Mehrzad Jafarzadeh; Kazem Mousavizadeh; Mohammad Taghi Joghataei; Mohammad Hashemi Bahremani; Majid Safa; S Mohsen Asghari
Journal:  Open Life Sci       Date:  2018-10-31       Impact factor: 0.938

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.